Experience

Intellijoint Surgical Inc.

• Canada
• Medical Device
• 100 - 200 Employee

• Business Development Manager, Canada

  • Nov 2021 - Present

  Canadian Sales won Q1 2022 Star Performer Canadian Sales won Q1 2022 Star Performer



GSK

• United Kingdom
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Pharmaceutical Representative, Respiratory

  • Jan 2019 - Nov 2021

  *Top Performer 2019

• Pharmaceutical Representative, Vaccines

  • Sep 2017 - Dec 2018



AstraZeneca

• United Kingdom
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Study Delivery Coordinator

  • Jan 2016 - Aug 2017



Antibe Therapeutics Inc.

• Canada
• Biotechnology Research
• 1 - 100 Employee

• Research Intern

  • May 2014 - Aug 2014

  • Devised a company assessment of the potential market outcome for lead drug ATB-346, contributing to investment for the drugs development • Researched existing data on the market of NSAIDs globally • Forecasted the market share of ATB-346 and presented findings to the senior management team • Assisted with Phase II design of clinical trials for ATB-346 • Researched competitors, patents, and any publications regarding hydrogen sulphide • Assisted with developing a corporate presentation for intended for perspective investors Show less



Queen's University

• Canada
• Higher Education
• 700 & Above Employee

• Undergraduate Research Assistant with Dr. Graham Cote

  • Jan 2014 - Apr 2014

  Performed a series of site directed mutations to the catalytic domain of Myosin Heavy Chain Kinase A (A-CAT) in order to determine which residues were essential for alpha-kinase activity. Binding activity was measured by fluorescence analysis of Mant-nucleotide binding to A-CAT Performed a series of site directed mutations to the catalytic domain of Myosin Heavy Chain Kinase A (A-CAT) in order to determine which residues were essential for alpha-kinase activity. Binding activity was measured by fluorescence analysis of Mant-nucleotide binding to A-CAT



Regenerative Research Foundation/Neural Stem Cell Institute

• United States
• Research Services
• 1 - 100 Employee

• Research Intern

  • May 2013 - Dec 2013

  Established stem cell-based disease model for retinal diseases: isolated RPE cells from bovine and developed an assay that could test a variety of compounds Established stem cell-based disease model for retinal diseases: isolated RPE cells from bovine and developed an assay that could test a variety of compounds



Queen's University

• Canada
• Higher Education
• 700 & Above Employee

• Snieckus Group Research

  • May 2012 - Aug 2012

  • Synthesized lignostilbene through a series of organic reactions • Practiced reactions including iron catalysed oxidative coupling, acetyl protection, and removal of phenols, oxidation of aldehydes, Mc Murray coupling using tetrachloride, hydrogenation • Handled moisture sensitive and inert atmosphere multi-step organic reactions • Analyzed organic compounds to determine chemical composition by NMR • Synthesized lignostilbene through a series of organic reactions • Practiced reactions including iron catalysed oxidative coupling, acetyl protection, and removal of phenols, oxidation of aldehydes, Mc Murray coupling using tetrachloride, hydrogenation • Handled moisture sensitive and inert atmosphere multi-step organic reactions • Analyzed organic compounds to determine chemical composition by NMR